Key statistics
On Monday, Elanco Animal Health Inc (ELAN:NYQ) closed at 14.55, -22.61% below its 52-week high of 18.80, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.69 |
---|---|
High | 14.85 |
Low | 14.38 |
Bid | 14.55 |
Offer | 14.75 |
Previous close | 14.66 |
Average volume | 4.64m |
---|---|
Shares outstanding | 494.33m |
Free float | 491.07m |
P/E (TTM) | -- |
Market cap | 7.25bn USD |
EPS (TTM) | -2.55 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 00:00 BST.
More ▼
Press releases
- Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose
- Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
- Elanco Provides Update on Contract Manufacturing Partner
- Elanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
- Elanco Announces Credelio Quattro Moves to Final FDA Administrative Review
- Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)
- Elanco Animal Health Reports Second Quarter 2024 Results
- Elanco Releases 2023 Environmental, Social and Governance Report, Delivering Healthier Outcomes for Animals, People, Planet and Enterprise
- Elanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement
More ▼